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Introduction: Sleep bruxism (SB) is defined as a stereotyped and periodic movement dis-
order, characterized by tooth grinding and/or clenching occurring during sleep, associated 
with rhythmic masticatory muscle activity. This condition isn’t a disease, but when exac-
erbated may cause an unbalance and changing of orofacial structures. Thus, it is necessary 
to obtain effective and safe treatments for the control and management of the bruxist 
patient. The treatment alternatives range from oral devices, pharmacological therapies to 
cognitive-behavioral techniques. Objective: This study, a systematic literature review hav-
ing as research bases MEDLINE, Cochrane, EMBASE, Pubmed, Lilacs and BBO, between 
the years of 1990 and 2008, with focus in randomized and quasi-randomized clinical tri-
als, systematic reviews and meta-analysis, had as objective to analyze and discuss possibili-
ties of treatment for sleep bruxism. Results: According to the literature analysis there is a 
lot of treatment options for the SB, but many of the therapies have no scientific support. 
Thus, the choice therapy should be based on scientific evidences and in clinical common 
sense, for an improvement in quality of life of the bruxist patient.
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INTRODUCTION
Sleep Bruxism (SB) is considered a move-
ment disorder related to sleep.1 This parafunction 
is characterized by non-functional teeth contact, 
which can occur in a conscious or unconscious 
way, manifested by grinding or clenching of teeth. 
This condition is not a disease, but when exacer-
bated may cause a pathophysiological unbalance 
of the stomatognathic system. Several therapeu-
tic modalities have been suggested, but there is 
no consensus on the most efficient.20
Due to its prevalence and injuries caused to 
the patients, the correct diagnosis shows great 
value to the development of appropriate treat-
ment protocols, which include therapeutics us-
ing devices and oral therapies, pharmacological 
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measures and cognitive-behavioral treatments 
(CBT). Thus, the objective of this systematic lit-
erature review is to discuss, based on scientific evi-
dence, treatment alternatives for the control and 
management of SB.
MATERIAL AND METHODS
A computerized search in MEDLINE, Co-
chrane, EMBASE, PubMed, Lilacs and BBO was 
performed. The research descriptors used were 
“sleep bruxism”, “treatment”, “drugs”, “medications” 
and “oral devices”, which were crossed in search 
engines. The initial list of articles was submitted 
to review by two reviewers, who applied inclusion 
criteria to determine the final sample of articles.
Inclusion criteria for the selecting articles were:
 » Articles published from January 1990 until 
July 2008.
 » Within a context of an evidence-based Den-
tistry, only randomized clinical trials (RCTs) 
and quasi-randomized trials, systematic re-
views and meta-analysis were included. Pilot 
studies were not included.
 » Studies should include therapies for the 
treatment of SB involving orodental, phar-
macological and/or cognitive-behavioral 
therapies.
 » Studies written in English, Spanish or Portu-
guese.
RESULTS
After applying the inclusion criteria 13 studies 
were selected and the Kappa index of agreement 
between reviewers was 1.00. Thus, these studies 
were grouped according to the therapeutic mo-
dalities: orodental, pharmacological or cognitive-
behavioral (Figs 1 and 2).
EvIDENCE-bASED DENTISTRy - 
SySTEMATIC REvIEw
Orodental treatments: oral appliances and 
occlusal rehabilitations
In a systematic review, Tsukiyama et al21 evalu-
ated the effects of occlusal adjustment as a treat-
ment for bruxism, temporomandibular disorders 
(TMD), headaches and chronic cervical pain. 
Eleven studies met the inclusion criteria and three 
of these studies evaluated occlusal adjustment as 
a therapy for bruxism. The literature analysis con-
cluded that there are no clinical studies showing 
that occlusal adjustment is superior to non-inva-
sive therapies for the SB and TMD.
Dubé et al,2 in a controlled, double-blind and 
crossover RCT assessed the efficacy and safety of 
an occlusal splint and a palatal splint in the reduc-
tion of the muscle activity and teeth clenching in 
a sample of nine patients with SB. The patients, 
randomly, used an occlusal splint or a palatal splint 
for a period of two weeks, and then the treatments 
FigurE 1 - Design of included studies. FigurE 2 - Types of therapies for SB.
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were swapped and the use was followed by an-
other two weeks. The therapies were evaluated 
by polysomnographic examinations. The authors 
found that there was a statistically significant re-
duction in the number of episodes of SB with the 
use of both treatments, with no differences due to 
the design of the devices.
In a controlled, double-blind and parallel RCT, 
Van der Zaag et al22 compared the effects of oc-
clusal and palatal splints in the management of 
SB. A sample of 21 patients were divided ran-
domly between the occlusal splint (n = 11) and 
the palatal splint (n = 10) groups. In these indi-
viduals two polysomnographic evaluations were 
performed, one conducted before the beginning 
of therapy and another after a treatment period of 
four weeks. The study results showed that neither 
the occlusal splint, nor the palatal splint had an 
influence on the SB or in relation to patient sleep.
Harada et al,5 in a controlled and crossover 
RCT, compared the effects of a stabilization 
splint and a palatal splint in the management 
of SB. The sample consisted of 16 patients with 
bruxism who were divided randomly into two 
groups (n = 8) according to the splint used, and 
muscle activity was evaluated by an electromyo-
graphic portable device. After a period of use of 
the splint by six weeks, followed by two months 
without using any splint, the individuals were 
swapped between groups and started using the 
splint that had not yet been used for another 
six weeks. The results of this study showed that 
both the occlusal splint and the palatal splint 
reduced the masseter muscle activity during 
the night immediately after appliance installa-
tion. However, no effects were observed after 2, 
4 and 6 weeks of use, and no differences were 
noted due to the splints designs.
Landry et al9 performed a RCT controlled and 
crossover comparing the effects of two therapies 
in the management of SB: in one patients received 
a mandibular advancement device (MAD), which 
involved two arches; and in the other therapy pa-
tients received a traditional occlusal splint. The 
sample consisted of 13 participants who under-
went polysomnographic examination, with diag-
nosis of SB. Based on these results, the authors 
concluded that short-term temporary use of the 
MAD is associated with a notable reduction in 
motor activity of SB, and to a lesser order the oc-
clusal splint also found a reduction of SB. How-
ever, the use of MAD in eight patients caused ad-
verse effects, such as pain and discomfort.
In a systematic review published in Cochrane, 
Macedo et al,12 evaluated the effectiveness of oc-
clusal splints as an alternative treatment for the 
SB. The authors conducted a computerized search, 
from 1966 to May 2007, including only random-
ized or quasi-randomized trials. The final sample 
of articles consisted of five RCTs. Occlusal splint 
therapy was compared to: palatal splint, mandibu-
lar advancement device, transcutaneous electrical 
neural stimulation (TENS) and no treatment. The 
authors concluded that there is not enough evi-
dence to affirm that the occlusal splint is effective 
in the treatment of SB.
Pharmacological treatments
Etzel et al3 evaluated the effects of L-trypto-
phan on the SB in a double-blind RCT. Using a 
portable electromyography device, a sample of 
eight patients identified as nocturnal bruxists, re-
ceived tryptophan (50 mg/kg) or placebo for 8 
days, followed by further 8 days with the drugs 
inverted. Diet and alimentary habits were moni-
tored during the experimental period. The study 
results showed no significant differences between 
therapies, suggesting that supplementation with 
L-tryptophan is ineffective in the treatment of SB.
In a double-blind randomized clinical trial, 
Mohamed et al13 evaluated 10 patients with SB, 
which received 25 mg of amitriptyline and 25 mg 
of placebo for one week each. The results showed 
that neither the intensity nor location of pain, 
and electromyographic activity of the masseter 
muscle were significantly affected by the tricyclic 
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antidepressant therapy. Based on this study, low 
doses of amitriptyline are not recommended for 
the control of sleep bruxism, or for the discom-
forts associated with this sleep disorder.
In another double-blind RCT involving ami-
triptyline, Raigrodski et al17 assessed the effects 
of this antidepressant on nocturnal activity of the 
masseter muscle and in duration of sleep in pa-
tients with bruxism. The sample consisted of 10 
women who received active treatment (amitrip-
tyline 25 mg/night) and inactive (placebo, 25 mg/
night) for a period of four weeks each. To assess 
the activity of masseter muscle a portable electro-
myography device was used. The results showed 
that administration of amitriptyline did not signif-
icantly decrease the activity of the masseter mus-
cle, neither significantly increase sleep duration.
The role of the dopaminergic system in the 
SB was studied by Lobbezoo et al,11 in a con-
trolled, double-blind and crossover RCT. A sam-
ple of 10 patients with SB received low doses 
of L-dopa associated with benserazide and was 
evaluated in a sleep laboratory. After the first 
night of adaptation, the second and third nights 
the patients received two doses (100 mg) of 
L-dopa or placebo, in a crossed design, with a 
dose one hour before bedtime and another four 
hours after the first. It was found that the use 
of L-dopa resulted in a decrease in the average 
number of bruxism episodes per hour of sleep, 
but this reduction proved to be modest, being 
only of the order of 26%.
Lavigne et al,10 in a controlled, double-blind 
and crossover RCT, evaluated the effects of bro-
mocriptine on the SB. The study sample consisted 
of seven patients with SB, evaluated by polysom-
nography. These patients underwent two weeks 
of active treatment or placebo and then remained 
a week with no treatment, after the treatments 
were crossed in the sample. The doses of bro-
mocriptine ranged from 1.25 mg to 7.5 mg (six 
days) up to 7.5 mg dose (8 days). Examining the 
results, bromocriptine did not reduce the frequen-
cy of episodes of bruxism during the night or the 
amplitude of contractions of the masseter muscle.
Assessing the effects of clonidine (0.3 mg) and 
propranolol (120 mg) on the SB, Huynh et al6 con-
ducted a controlled, double-blind and crossover 
RCT comparing these drugs to placebo. A sample 
of 25 patients with a history and diagnosis of SB, 
was divided randomly into the groups, participat-
ing in this study and were monitored by polysom-
nographic examination. The results showed that 
propranolol (n = 10) did not affect the SB, where-
as clonidine (n = 16) decreased sympathetic tone 
in the minute preceding the onset of SB, reducing 
the SB by preventing activation of the sequence 
of autonomic and motor events characteristics of 
the same. Hypotension was also observed in the 
morning in 19% of the studied patients.
A study not selected by the inclusion criteria, 
as it was not randomized, but with interesting 
findings, was of Saletu et al,18 in which a blind and 
controlled study investigated the acute effects of 
clonazepam on the SB. The sample consisted of 
10 patients who received prior treatment with oc-
clusal splint. Polysomnography and psychometry 
were used to evaluate the patients who received 
placebo or clonazepam. The administration of 
1 mg of clonazepam significantly improved the 
index of SB and also the quality of sleep, with a 
good tolerability to drug.
Cognitive-behavioral treatments
Ommerborn et al15 conducted a RCT com-
paring the occlusal splint (n = 29) to a cognitive-
behavioral therapy (CBT) (n = 28) in the man-
agement of the SB. The CBT consisted of mea-
sures such as problem solving, progressive muscle 
relaxation, nocturnal biofeedback and recreation 
training. Treatment for both groups lasted 12 
weeks, and patients were examined pre and post-
treatment and 6 months after conclusion of the 
study. The findings showed a significant reduction 
in activity of the SB in the two groups, but the ef-
fects were small. Moreover, the CBT group had a 
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tendency to return to baseline of the study when 
compared to occlusal splint.
DISCUSSION
Considerations about the subject should always 
be performed through a critical reading of the 
methodology used by different authors. The use of 
the basic research principles allows the researchers 
to try to control as best as possible the biases of the 
study, generating higher levels of evidence. Thus, 
methodological criteria such as sample size calcu-
lation, randomization, blinding, control of involved 
factors and calibration intra and inter-examinators, 
become important tools to qualify the level of the 
generated scientific evidence.19
Within this context, of an evidence-based den-
tistry, it appears that the most common types of 
studies published in Brazilian journals correspond 
to studies of low potential for direct clinical ap-
plication: in vitro studies (25%), narrative reviews 
(24%) and case reports (20%). The low number 
of studies with greater strength of evidence shows 
the necessity to increase knowledge of evidence-
based methods among Brazilian researchers.14
According to the systematic literature review, 
it appears when evaluating therapeutic modali-
ties for the control and management of the SB, 
that the selected studies presented in this ar-
ticle showed, for the most part, short samples 
and a short follow-up time. Thus, with small and 
unrepresentative samples, it is difficult to ex-
trapolate the results to the general population. 
Moreover, many of the selected studies had a 
relatively short follow-up time, demonstrating 
the necessity for a larger longitudinal follow-up 
time to evaluate the real efficacy and safety of 
proposed treatments, whether orodental, phar-
macological or cognitive-behavioral therapies. 
This becomes important because many drugs 
can cause tolerance and dependence effects in 
patients when used for long periods.
When analysing oral appliances as a treatment 
for the SB, it appears that there is no significant 
scientific evidences that the occlusal splint treats 
the SB, but benefits as the reduction in tooth wear 
are observed.12,22 Only two studies found a reduc-
tion in episodes of SB and in the masseter elec-
tromyographic condition with the use of splints, 
but one of these studies had a follow-up time of 
just two weeks, while the other only found an 
improvement immediately after installing the ap-
pliance, being that in subsequent evaluations im-
provements have not been observed.2,5 Still, when 
comparing the occlusal splint to palatal splint 
(without occlusal covering) there is similarity in 
results between the two treatment modalities.2,5
On the other hand, the mandibular ad-
vancement device, similar to appliances used 
for treatment of snoring and obstructive sleep 
apnea syndrome (OSAS), showed a greater re-
duction in episodes of SB when compared to 
occlusal splint. However, the exact mechanism 
that explains this reduction continues to be in-
vestigated. The hypotheses are focused on the 
size and configuration of the device, presence 
of pain, reduction in freedom of movement or 
change in upper airway patency.9
In patients with Sleep Bruxism the treatment 
option for minimally invasive and reversible ther-
apies should be first choice in treatment protocols. 
Already the option for irreversible treatments, 
such as occlusal adjustment, have no scientific ba-
sis to support it, as there is no scientific evidence 
that occlusal adjustment treats or prevents Sleep 
Bruxism and TMD.8,21
Regarding to the pharmacological treatments, 
clonidine has a major role, but is associated with 
secondary adverse effects, demonstrating the ne-
cessity for further controlled RCTs with longer 
follow-up time to verify its real efficacy and safety.6 
Thus, clonazepam becomes a safer alternative and 
with satisfactory results in the short term.7,18 It is 
important to mention here that the clonazepam, 
like other benzodiazepine drugs, may exacerbate 
OSAS. In other words, if the patient has a diag-
nosis of bruxism and OSAS, the clonazepam may 
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be contraindicated. Another drug that also shows 
good results in the control and management of SB 
is L-dopa.11 In relation to amitriptyline, there is no 
scientific evidence to justify its use in patients with 
SB,13,17 same fact occurs with propranolol,6 trypto-
phan3 and bromocriptine.10
Target of many current studies in the Orofa-
cial Pain investigations, due to its analgesic and 
antinociceptive properties, botulinum toxin has 
yet no RCTs analyzing its role in the treatment of 
SB. What is observed in the literature are studies 
evaluating botulinum toxin in situations associ-
ated with bruxism, such as muscle hyperactivity 
and myofascial pain,4 or studies without signifi-
cant levels of evidence. In the future, with the per-
formance of controlled RCTs, with representative 
samples and long follow-up time, botulinum toxin 
can be assessed as to its real effectiveness and safe-
ty for the treatment of SB.
Alternative cognitive-behavioral treatments 
may act in combination with other therapies, pro-
ceeding as an adjunct in the management of the 
SB. The awareness and patient education about 
their situation and the importance of changing 
habits that may be influencing and perpetuat-
ing their condition is important. Measures such 
as problem solving, muscle relaxation, noctur-
nal biofeedback, sleep hygiene and recreation, in 
other words, alternatives that reduce anxiety and 
stress, become tools for optimal results in situa-
tions of SB.15,16
CONCLUSIONS
 » The occlusal splint seems to be an accept-
able and safe treatment alternative in the 
short and medium terms, while the clonaz-
epam, among pharmacological treatments, 
stood out as a therapeutic option in the 
short term, because in the long term it can 
cause dependence.
 » The results of this systematic literature re-
view seems to indicate that the mandibular 
advancement device and clonidine are the 
most promising experimental treatments for 
the SB, however both are associated with 
secondary adverse effects.
 » There is need for further randomized clinical 
trials, based on representative samples and 
long follow-up time, to assess the effective-
ness and safety of proposed treatments for 
the control and management of the SB.
 » Cognitive-behavioral therapies such as psy-
chotherapy, biofeedback, physical exercise 
and lifestyle changes, which are aimed at 
stress reduction, may be auxiliary in the 
treatment of SB.
 » The SB continues to be a condition of com-
plex etiology, associated with numerous 
treatments with often undefined prognosis. 
Thus, conservative treatments, minimally in-
vasive and safe should be first choice, with 
the patient assisted by a multidisciplinary 
team, aiming at restoring quality of life.
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